ERYTECH Pharma S.A.
Develops red blood cell-based therapies for cancer and orphan diseases.
ERYP | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417360 (+2 more)
- LEI:
- 969500U8ZZCODU8A9374
- Country:
- France
- Address:
- 60 AVENUE ROCKEFELLER, 69008 LYON
- Website:
- https://phaxiam.com/
- Sector:
- Manufacturing
Description
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-11-09 08:00 |
ERYTECH présentera à l’occasion de la 12ème Conférence Jefferies Global London …
|
French | 278.7 KB | ||
| 2021-11-05 18:21 |
Information mensuelle relative au nombre total de droits de vote et d’actions c…
|
French | 212.6 KB | ||
| 2021-11-05 18:21 |
Monthly information related to total number of voting rights and shares composi…
|
English | 121.4 KB | ||
| 2021-10-25 07:00 |
ERYTECH annonce les résultats de l’étude de phase 3 TRYbeCA-1 évaluant eryaspas…
|
French | 305.2 KB | ||
| 2021-10-25 07:00 |
ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients…
|
English | 293.9 KB | ||
| 2021-10-07 18:00 |
Monthly information related to total number of voting rights and shares composi…
|
English | 120.9 KB | ||
| 2021-10-07 18:00 |
Information mensuelle relative au nombre total de droits de vote et d’actions c…
|
French | 212.1 KB | ||
| 2021-10-04 22:05 |
ERYTECH annonce la détermination de la Dose Maximale Tolérée dans le cadre de l…
|
French | 274.2 KB | ||
| 2021-10-04 22:05 |
ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Spo…
|
English | 272.0 KB | ||
| 2021-09-28 22:05 |
ERYTECH participera à la conférence HealthTech Innovation Days (HTID) organisée…
|
French | 255.1 KB | ||
| 2021-09-28 22:05 |
ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biote…
|
English | 247.9 KB | ||
| 2021-09-22 18:30 |
ERYTECH annonce la mise à disposition de son rapport financier semestriel 2021
|
French | 235.2 KB | ||
| 2021-09-22 18:30 |
ERYTECH Announces the Availability of its Half-Year Financial Report 2021
|
English | 221.4 KB | ||
| 2021-09-21 14:00 |
Rapport financier semestriel 2021
|
French | 449.5 KB | ||
| 2021-09-20 22:05 |
ERYTECH fait le point sur ses activités et publie ses résultats semestriels 2021
|
French | 420.3 KB |
Automate Your Workflow. Get a real-time feed of all ERYTECH Pharma S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ERYTECH Pharma S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ERYTECH Pharma S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-06-23 | N/A | Other | Other | 3,697,533 | 2,255,495.13 EUR |
| 2023-06-23 | N/A | Other | Other | 71,839 | 43,821.79 EUR |
| 2023-06-23 | N/A | Other | Other | 54,862 | 33,465.82 EUR |
Peer Companies
